The purpose of this review is to summarize the recent studies supporting the role of IL-17 in JIA and to highlight how these studies have led to the approval of the use of monoclonal anti-interleukin (IL)-17A antibodies for the treatment of the JIA subtypes enthesitis-related arthritis (ERA) and juvenile psoriatic arthritis (JPsA). Here, IL17A is linked to psoriasis-related juvenile idiopathic arthritis.